Annual Research Review: Prevention of psychosis in adolescents – systematic review and meta‐analysis of advances in detection, prognosis and intervention
| Autor: | Ilaria Bonoldi, Gonzalo Salazar de Pablo, Celso Arango, Aranzazu Fernandez-Rivas, Helen Baldwin, Christoph U. Correll, Paolo Fusar-Poli, Julio David Vaquerizo Serrano, Carmen Moreno, Ana Catalan, Pierluca Mosillo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
clinical high-risk state for psychosis Psychological intervention 0302 clinical medicine prevention ultra-high-risk Developmental and Educational Psychology psychosis First episode education.field_of_study 05 social sciences perceived social stress Prognosis behavior assessment system indicated prevention Anxiety Disorders Psychiatry and Mental health young-people Cognitive remediation therapy Schizophrenia Meta-analysis randomized controlled-trial Female Psychology Antipsychotic Agents 050104 developmental & child psychology medicine.medical_specialty Psychosis Adolescent Population 03 medical and health sciences medicine Humans reduced prepulse inhibition 0501 psychology and cognitive sciences first-episode Psychiatry education childhood help-seeking adolescents psychosis risk evidence prediction Publication bias medicine.disease Cognitive Remediation clinical high-risk schizophrenia meta-analysis Psychotic Disorders quality-of-life Pediatrics Perinatology and Child Health adolescence 030217 neurology & neurosurgery |
| Zdroj: | Addi. Archivo Digital para la Docencia y la Investigación instname Catalan, A, Salazar De Pablo, G, Vaquerizo Serrano, J, Mosillo, P, Baldwin, H, Fernández-rivas, A, Moreno, C, Arango, C, Correll, C U, Bonoldi, I & Fusar-poli, P 2021, ' Annual Research Review: Prevention of psychosis in adolescents – systematic review and meta-analysis of advances in detection, prognosis and intervention ', Journal of Child Psychology and Psychiatry, vol. 62, no. 5, pp. 657-673 . https://doi.org/10.1111/jcpp.13322 Addi: Archivo Digital para la Docencia y la Investigación Universidad del País Vasco |
| ISSN: | 1469-7610 0021-9630 |
| DOI: | 10.1111/jcpp.13322 |
| Popis: | Background The clinical high-risk state for psychosis (CHR-P) paradigm has facilitated the implementation of psychosis prevention into clinical practice; however, advancements in adolescent CHR-P populations are less established. Methods We performed a PRISMA/MOOSE-compliant systematic review of the Web of Science database, from inception until 7 October 2019, to identify original studies conducted in CHR-P children and adolescents (mean age = 36 months.Interventions: There was not enough evidence to recommend one specific treatment (including cognitive behavioural therapy) over the others (including control conditions) to prevent the transition to psychosis in this population. Randomised controlled trials suggested that family interventions, cognitive remediation and fish oil supplementation may improve cognition, symptoms and functioning. At baseline, 30% of CHR-P adolescents were prescribed antipsychotics and 60% received psychotherapy. Conclusions It is possible to detect and formulate a group-level prognosis in adolescents at risk for psychosis. Future interventional research is required. G.S.d.P. and J.V.S. are supported by the Alicia Koplowitz Foundation. The study has been supported by the Spanish Ministry of Science, Innovation, and Universities, Instituto de Salud Carlos III, European Regional Development Fund 'A way of making Europe,' Centro de Investigacion Biomedica en Red Salud Mental, Madrid Regional Government; and Fundacion Mutua Madrilena. A.C. has received personal fees from Janssen and grant support from the Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness. C.A. has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. C.M. has acted as consultant or participated in DMC for Janssen, Servier, Lundbeck, Nuvelution, Angelini and Otsuka and has received grant support from European Union Funds and Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiviness. C.U.C. has been a consultant and/or adviser to or has received honoraria from: Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen and Otsuka. He served on a Data Safety Monitoring Board for Boehringer-Ingelheim, Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a shareholder of LB Pharma. P.F-P. has been a consultant to and received research funds from Lundbeck and received honoraria from Menarini and Angelini |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|